Download PDF
Thromb Haemost 1996; 76(06): 0998-1003
DOI: 10.1055/s-0038-1650699
Original Article
Schattauer GmbH Stuttgart

Induction of Human Factor VIII Inhibitors in Rats 2: Fine Mapping of Rat anti-Human rFVIII Antibodies

L G Levin
3   The Department of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, NC
4   The Center for Thrombosis and Hemostasis, University of North Carolina at Chapel Hill, Chapel Hill, NC
,
M Jarvis
6   The Department of Internal Medicine, University of California at Davis, USA
,
J Powell
6   The Department of Internal Medicine, University of California at Davis, USA
,
J A Harrison
5   The Department of Pediatrics, University of California at Davis, USA
,
H M Reisner
1   The Departments of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC
2   The Department of Pathology, University of North Carolina at Chapel Hill, Chapel Hill, NC
4   The Center for Thrombosis and Hemostasis, University of North Carolina at Chapel Hill, Chapel Hill, NC
› Author Affiliations
Further Information

Publication History

Received 10 August 1995

Accepted after resubmission 12 June 1996

Publication Date:
11 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Inhibiting antibodies in patients with hemophilia A pose a significant therapeutic dilemma in the treatment of bleeding episodes. The genetic factors which predispose hemophiliacs to inhibitors and the optimal method for inhibitor suppression remain obscure. Hence, an animal model of the human FVIII inhibitor response is of potential value. Sprague-Dawley rats immunized with human recombinant FVIII (rFVIII) subsequently developed abnormal coagulation parameters coincident with the development of an immune response to the human protein. The epitopes for the resultant rat anti-rFVIII antibodies were mapped using a random fragment expression library constructed from the FVIII cDNA. Antigenic regions located within the Al, First and Second Acidic and B domains were mapped. Rat immunoglobulins reactive with the individual epitopes were immunoaffinity purified and assayed for inhibitory activity. Several of the epitopes mapped using the rat antibodies were similar to regions previously shown to be antigenic for human inhibitors. By contrast, no epitopes were mapped to the A2 domain with the techniques used. This may be due to the possible presence of conformational epitopes in this area which cannot undergo fragmentation and still retain antigenicity or the presence of relatively low concentrations of antibodies to this region. The rat model shares some similarity with both the auto- and alloimmune human response to FVIII and therefore may be a valuable model for studies on the induction and suppression of the inhibitor response.

 

  • References

  • 1 Jarvis MA, Levin LG, Harrison JA, De Pianto DJ, Suzuki CM, Ziaja CL, Brown JE, Jolly KW, Reisner HM, Abildgaard CF, Powell JS. Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: a small animal model for humans with high responder inhibitor phenotype. Thromb Haemost 1996; 75 (02) 318-325
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Kessler CM. An Introduction to Factor VIII Inhibitors: The Detection and Quantitation. Amer Jof Med 1991; 91: 1s-5s
    PubMedGoogle Scholar
  • 3 Fulcher CA, de Graaf Mahoney S, Roberts JR, Kasper CA, Zimmerman TS. Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments. Proc Natl Acad Sci USA 1985; 82: 7728-7732
    CrossrefPubMedGoogle Scholar
  • 4 Fulcher CA, de Graaf Mahoney S, Zimmerman TS. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 1987; 69: 1475-1480
    PubMedGoogle Scholar
  • 5 Fulcher CA, Lechner K, Mahoney S. Immunoblot analysis shows changes in Factor VIII inhibitor chain specificity in factor VIII inhibitor patients over time. Blood 1988; 72: 1348-1356
    PubMedGoogle Scholar
  • 6 Ware J, Toomey JR, Stafford DW. Localization of a factor VUI-inhibiting epitope to a region between residues 338 and 362 of factor VIII heavy chain. Proc Natl Acad Sci USA 1988; 85: 3165-3169
    CrossrefPubMedGoogle Scholar
  • 7 Lubahn BC, Ware J, Stafford DW, Reisner HM. Identification of a F VIII epitope recognized by a human hemophilic inhibitor. Blood 1989; 73: 497-499
    PubMedGoogle Scholar
  • 8 Scandella D, Mahoney S, Mattingly M, Roeder D, Timmons L, Fulcher CA. Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli. Proc Natl Acad Sci USA 1988; 85: 6152-6156
    CrossrefPubMedGoogle Scholar
  • 9 Scandella D, Mattingly M, de Graaf S, Fulcher CA. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood 1989; 74: 1618-1626
    PubMedGoogle Scholar
  • 10 Scandella D, Timmons L, Mattingly M, Trabold N, Hoyer LW. A soluble recombinant factor VIII fragment containing the A2 domain binds to some human anti-factor VIII antibodies that are not detected by immunoblotting. Thromb Haemost 1992; 67: 665-671
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Scandella D, Mattingly M, Prescott R. A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies that bind A2. Blood 1993; 82: 1767-1775
    PubMedGoogle Scholar
  • 12 Healey JF, Lubin IM, Nakai H, Saenko E, Hoyer LW, Scandella D, Lollar P. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem 1995; 270: 14505-14509
    CrossrefPubMedGoogle Scholar
  • 13 Ware J, MacDonald MJ, Lo M, de Graaf S, Fulcher CA. Epitope mapping of human FVIII inhibitor antibodies by site-directed mutagenesis of a factor VIII polypeptide. Blood Coagul and Fibrinolysis 1992; 3: 703-716
    PubMedGoogle Scholar
  • 14 Nakai H, Mondorf W, Saenko EL, Scandella D. The presence of anti-A1 and B Domain antibodies in Factor VIII inhibitor patients. Blood 1995; 86 (Suppl. 01) 190a
    PubMedGoogle Scholar
  • 15 Laemmli UK. Cleavage of structure protein during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
    CrossrefPubMedGoogle Scholar
  • 16 Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd Edition. Cold Spring Harbor Laboratory Press; Plainville, NY: 1989. volume 3 18.17-18.18
    Google Scholar
  • 17 Engvall E, Perlman P. Enzyme-linked immunosorbent assay (ELISA); Quantitative assay of immunoglobulin G. Immunochemistry 1971; 8: 871-879
    CrossrefPubMedGoogle Scholar
  • 18 Kasper C, Aledort L, Aronson D, Counts R, Edson J, van Eys J, Fratatoni J, Green D, Hampton J, Hilgartner M, Levine P, Lazerson J, McMillan C, Penner J, Shapiro S, Shulman N. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34 (02) 612
    PubMedGoogle Scholar
  • 19 Foster PA, Fulcher CA, Houghten RA, De Graaf Mahoney S, Zimmerman TS. Localization of binding regions of a murine monoclonal anti-factor VIII antibody and a human antifactor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine 351-serine 365 of the factor VIII heavy chain. J Clin Invest 1988; 82: 123-128
    CrossrefPubMedGoogle Scholar
  • 20 Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH. Targeted disruption of the mouse factor VIII gene produces a model of Haemophilia A. Nature Genetics 1995; 10: 119-121
    CrossrefPubMedGoogle Scholar
  • 21 Tinlin S, Webster S, Giles AR. The development of homologous (canine/ anti-canine) antibodies in dogs with haemophilia A (factor VIII deficiency): A ten-year longitudinal study. Thromb Haemost 1993; 69: 21-24
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Sauger A, Laulan A, Germain C, Paolantonacci P, Dhainaut F, Sultan Y, Bartholeyns J. Immunogenicity of a recombinant deleted FVIII compared to the plasma derived FVIII in the model of humanized-SCID mice. Thromb Haemost 1995; 37: 1213a
    PubMedGoogle Scholar
  • 23 Eaton DL, Wood WI, Eaton D, Hass PE, Hollingshead P, Wion K, Mather J, Lawn RM, Vehar GA, Gorman C. Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule. Biochemistry 1986; 25: 8343-8347
    CrossrefPubMedGoogle Scholar
  • 24 Gitschier J, Kogan S, Levinson B, Tuddenham EGD. Mutations of factor VIII cleavage sites in hemophilia A. Blood 1988; 72: 1022-1028
    CrossrefPubMedGoogle Scholar
  • 25 Toole JJ, Pittman DD, Orr EC, Murtha P, Wasley LC, Kaufman RJ. A large region (=95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc Natl Acad Sci USA 1986; 83: 5939-5942
    CrossrefPubMedGoogle Scholar
  • 26 Tison T, Vianello F, Carraro P, Radossi P, Rosato A, Dazzi F, Girolami A. High incidence of non-inhibitory antifactor VIII (FVIII) antibodies in haemophilia A patients: relevance on FVIII half-life. Thromb Haemost 1995; 73: 1012
    PubMedGoogle Scholar
  • 27 Shima M, Fulcher CA, de Graaf Mahoney S, Houghten RA, Zimmerman TS. Localization of the binding site for a factor VIII activity neutralizing antibody to amino acid residues Asp 1663-Ser 1669. J Biol Chem 1988; 263: 10198-10203
    PubMedGoogle Scholar
  • 28 Tiarks C, Pechet L, Anderson J, Mole JE, Humphreys RE. Characterization of a factor VIII immunogenic site using factor VIII synthetic peptide 1687 to 1695 and rabbit anti-peptide antibodies. Thromb Res 1992; 65 (03) 301-310
    CrossrefPubMedGoogle Scholar
  • 29 Curtis J, Helgerson E, Parker E, Lollar P. Isolation and characterization of thrombin-activated human factor VIII. J Biol Chem 1994; 269: 6246-6251
    PubMedGoogle Scholar
  • 30 Foster PA, Fulcher CA, Houghten RA, Zimmerman TS. An immunogenic region within residues Val 1670-Glu684 of the factor VIII light chain induces antibodies which inhibit binding of factor VIII to von Willebrand factor. J Biol Chem 1988; 263: 5230-5234
    PubMedGoogle Scholar
  • 31 Scandella D, Kessler C, Esmon P, Hurst D, Courter S, Gomperts E, Felch M, Prescott R. and the Recombinate and Kogenate Study Groups. Epitope specificity and functional characterization of Factor VIII inhibitors. In: Inhibitors to Coagulation Factors Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White GC. eds Plenum Press; New York, NY: 1995: 47-64
  • 32 Scandella D, Gilbert GE, Shima M, Nakai H, Eagleson C, Felch M, Prescott R, Rajalakshmi KJ, Hoyer LW, Saenko E. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 1995; 86 (05) 1811-1819
    PubMedGoogle Scholar
  • 33 Ware J, MacDonald MJ, Lo M, de Graaf S, Fulcher CA. Epitope mapping of human FVIII inhibitor antibodies by site-directed mutagenesis of a factor VIII polypeptide. Blood Coagul and Fibrinolysis 1992; 3: 703-716
    PubMedGoogle Scholar
  • 34 Healey JF, Lubin IM, Hiroaki N, Evgueni L, Saenko L, Hoyer LW, Scandella D, Lollar P. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of Human Factor VIII. J Biol Chem 1995; 270: 14505-14509
    CrossrefPubMedGoogle Scholar
  • 35 Elder B, Lakich D, Gitchier J. Sequence of the murine factor VIII cDNA. Genomics 1993; 16: 374-379
    CrossrefPubMedGoogle Scholar